Browsing by Author "Ongun S."
Now showing 1 - 5 of 5
Results Per Page
Sort Options
Item Impact of previous SWL on ureterorenoscopy outcomes and optimal timing for ureterorenoscopy after SWL failure in proximal ureteral stones(Springer, 2020) Irer B.; Sahin M.O.; Erbatu O.; Yildiz A.; Ongun S.; Cinar O.; Cihan A.; Sen V.; Ucer O.; Kizilay F.; Bozkurt O.Purpose: We aimed to evaluate the impact of previous unsuccessful shock wave lithotripsy (SWL) therapy on ureterorenoscopy (URS) outcomes in proximal ureteral stones and to define whether there is any optimal timing for safe URS after SWL. Methods: The patients who underwent URS for proximal ureteral stones between the years 2015 and 2018 in eight centers were included. Patients were divided into two groups according to previous SWL history; group 1 consisted of patients without SWL before URS for the stone [SWL (−)] and group 2 consisted of patients with a previous SWL for the stone [SWL (+)]. Demographics, operation outcomes and stone characteristics were compared between these two groups. Regarding the complication and success rates, optimal timing for URS after SWL for the stone was calculated with receiver operator characteristics curve analysis. Results: Totally 638 patients were included (group 1: 466 patients and group 2: 172 patients). The operation and hospitalization times, rate of ureteral stenting and complications were significantly higher in group 2. Stone free status was similar between the groups. Optimal timing for URS after SWL was calculated as 16.5 days (AUC = 0.657, p = 0.012) with a sensitivity of 68% and specificity of 72%, regarding the complication rates. Complication rates were significantly higher in patients who were operated before 16.5 days (27.7% vs 6.5%, p < 0.001). Conclusions: The optimal timing; 2–3 weeks delay of the URS procedure after unsuccessful SWL may decrease complication rates according to our results. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature.Item Predictive Factors of Ureterorenoscopy Outcomes in Proximal Ureteral Stones: A Multicenter Study of Aegean Study Group of the Society of Urological Surgery(S. Karger AG, 2020) Sen V.; Irer B.; Erbatu O.; Yildiz A.; Ongun S.; Cinar O.; Cihan A.; Sahin M.O.; Ucer O.; Kizilay F.; Bozkurt O.Introduction: We aimed to evaluate the predictive factors in a holistic manner for ureterorenoscopy (URS) outcomes in proximal ureteral stones by a multicenter study. Materials and Methods: The data of patients who underwent URS for proximal ureteral stones between the years 2015 and 2018 in eight centers were recorded retrospectively. Patients were divided into two groups according to URS success: Group 1 consisted of patients with successful URS, and Group 2 consisted of patients with unsuccessful URS. The two groups were compared in terms of risk factors, stone, and clinical characteristics of patients. Results: A total of 638 patients were included in the study. Group 1 consisted of 527 (82.6%) patients, and Group 2 consisted of 111 (17.4%) patients. In multivariate logistic analysis, the key risk factors for URS success was found to be age (OR = 0.980, 95% [CI] = 0.963-0.996, p = 0.018), stone area (OR = 0.993, 95% [CI] = 0.989-0.997, p = 0.002), and operation time (OR = 0.981, 95% [CI] = 0.968-0.994, p = 0.005). Conclusions: To make the treatment decision of proximal ureteral stones, it is necessary to examine several parameters including available equipment, stone, and patient characteristics. Physicians should keep these risk factors in mind in the decision of treatment options. © 2019 S. Karger AG, Basel.Item Nation-wide analysis of the impact of Covid-19 pandemic on daily urology practice in Turkey(Blackwell Publishing Ltd, 2021) Bozkurt O.; Sen V.; Irer B.; Sagnak L.; Onal B.; Tanidir Y.; Karabay E.; Kaya C.; Ceyhan E.; Baser A.; Duran M.B.; Suer E.; Celen I.; Selvi I.; Ucer O.; Karakoc S.; Sarikaya E.; Ozden E.; Deger D.; Egriboyun S.; Ongun S.; Gurboga O.; Asutay M.K.; Kazaz I.O.; Yilmaz I.O.; Kisa E.; Demirkiran E.D.; Horsanali O.; Akarken I.; Kizer O.; Eren H.; Ucar M.; Cebeci O.O.; Kizilay F.; Comez K.; Mercimek M.N.; Ozkent M.S.; Izol V.; Gudeloglu A.; Ozturk B.; Akbaba K.T.; Polat S.; Gucuk A.; Ziyan A.; Selcuk B.; Akdeniz F.; Turgut H.; Sabuncu K.; Kaygisiz O.; Ersahin V.; Kahraman H.I.; Guzelsoy M.; Demir O.Objective: To present a nation-wide analysis of the workload of urology departments in Turkey week-by-week during Covid-19 pandemic. Methodology: The centres participating in the study were divided into three groups as tertiary referral centres, state hospitals and private practice hospitals. The number of outpatients, inpatients, daily interventions and urological surgeries were recorded prospectively between 9-March-2020 and 31-May-2020. All these variables were recorded for the same time interval of 2019 as well. The weekly change of the workload of urology during pandemic period was evaluated, also the workload of urology and the distributions of certain urological surgeries were compared between the pandemic period and the same time interval of the year 2019. Results: A total of 51 centres participated in the study. The number of outpatients, inpatients, urological surgeries and daily interventions were found to be dramatically decreased by the 3rd week of pandemics in state hospitals and tertiary referral centres; however, the daily urological practice were similar in private practice hospitals throughout the pandemic period. When the workload of urology in pandemic period and the same time interval of the year 2019 were compared, a huge decrease was observed in all variables during pandemic period. However, temporary measures like ureteral stenting, nephrostomy placement and percutaneous cystostomy have been found to increase during Covid-19 pandemic compared with normal life. Conclusions: Covid-19 pandemic significantly affected the routine daily urological practice likewise other subspecialties and priority was given to emergent and non-deferrable surgeries by urologists in concordance with published clinical guidelines. © 2020 John Wiley & Sons LtdItem Effects of mirabegron on JJ stent-related symptoms: A multicentric study(Blackwell Publishing Ltd, 2021) Cinar O.; Tanidir Y.; Ozer S.; Cizmeci S.; Erbatu O.; Ozdemir T.; Girgin R.; Ongun S.; Ucer O.; Kizilay F.; Sen V.; Irer B.; Bozkurt O.Aims of the study: To investigate the effect of mirabegron 50 mg/daily for JJ stent-related symptoms after ureteroscopic stone surgery. Methods: Medical records of 145 patients who were given a single daily oral dose of 50 mg of mirabegron for relieving stent-related symptoms were retrospectively analysed. Demographic and clinical data and stone parameters were recorded. All participants completed the Turkish version of the Ureter Symptom Score Questionnaire (USSQ-T) on the postoperative 7th day, and again after at least 3 weeks, before JJ stent removal. The severity of stent-related symptoms was statistically compared before and after the mirabegron treatment. Results: The mean urinary symptoms score decreased significantly from 30.87 ± 9.43 to 22.61 ± 6.78 (P <.0001), mean body pain score decreased significantly from 21.82 ± 11.22 to 14.03 ± 7.52 (P <.0001), mean work performance score decreased from 10.50 ± 8.61 to 7.02 ± 6.51 (P <.0001) and mean general health score decreased significantly from 15.43 ± 6.50 to 11.12 ± 3.70 (P <.0001). The mean sexual matters score significantly decreased from 3.88 ± 3.40 to 2.48 ± 2.03 (P <.0001), the additional problem score decreased from 9.31 ± 4.61 to 6.51 ± 2.83 (P <.0001) and the overall quality of life (QoL) score decreased from 5.18 ± 1.94 to 4.23 ± 1.71 after mirabegron use (P <.0001). Conclusion: Daily use of 50 g of mirabegron significantly improved stent-related symptoms, sexual matters and quality of life. © 2020 John Wiley & Sons LtdItem Mechanisms and grading of nocturia: Results from a multicentre prospective study(John Wiley and Sons Inc, 2021) Bozkurt O.; Irer B.; Kizilay F.; Erbatu O.; Sen V.; Cinar O.; Ongun S.; Cihan A.; Ozdemir T.; Tasdemir D.; Ucer O.Objective: To identify the pathophysiological mechanisms of nocturia and the correlation of these mechanisms with nocturia severity. Methodology: After approval by the local ethics committee, all patients with nocturia (≥1 nocturnal void/night) were included and filled the Overactive Bladder questionnaire, Nocturia Quality of Life, Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (male), International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms (female) and 3-day frequency-volume chart. Patients were divided into three groups according to the severity of nocturia: group 1 consisted of patients with mild (1-2 voids/night), group 2 with moderate (3-4 voids/night) and group 3 with severe nocturia (>4 voids/night). Comparative analysis was performed between groups, and P <.05 was deemed as statistically significant. Results: About 68.1%, 64.1% and 8.7% of the patients had nocturnal polyuria (NP), reduced bladder capacity and global polyuria, respectively. 42.7% of the patients had mixed nocturia. 6.1% of the patients did not comply with the aforementioned subtypes and defined as isolated nocturia. Regarding the severity of nocturia, 155 (41%) patients had mild, 167 (45%) patients had moderate and 57 (15%) patients had severe nocturia. Increased nocturia severity was related with decreased quality of life; higher age, urinary tract symptom scores, nocturnal urine volume, evening fluid consumption and beta-blocker medication rates. Increased nocturia severity was also associated with higher NP, global polyuria and reduced bladder capacity rates. Conclusions: Nocturia mechanisms may vary between mild and moderate to severe nocturia groups according to the present study. Nocturia grading with identification of subtypes may help for better standardisation of the diagnostic and treatment approaches as well as for the design of future clinical trials. © 2020 John Wiley & Sons Ltd